Phio Pharmaceuticals Corp. (NASDAQ: PHIO)
$4.88
+0.2100 ( +4.50% ) 17.0K
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Market Data
Open
$4.88
Previous close
$4.67
Volume
17.0K
Market cap
$2.32M
Day range
$4.24 - $4.82
52 week range
$4.24 - $29.07
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 18 | Jul 12, 2024 |
8-k | 8K-related | 15 | Jul 05, 2024 |
8-k | 8K-related | 16 | Jul 02, 2024 |
8-k | 8K-related | 14 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 11, 2024 |
4 | Insider transactions | 1 | Jun 10, 2024 |
8-k | 8K-related | 15 | May 28, 2024 |
8-k | 8K-related | 18 | May 17, 2024 |
10-q | Quarterly Reports | 48 | May 09, 2024 |
8-k | 8K-related | 15 | May 09, 2024 |